Company / Cash & Equivalents
Zymeworks Inc. Cash & Equivalents History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$41.2M
FY2025
5-year range
$41.2M / $400.9M
FY2021-FY2025
Trend
-37.7%
vs FY2024
Sector context
#189 of 207
Health Care
What the data says
Among 207 Health Care companies, Zymeworks Inc. is in the bottom 9% for cash & equivalents. Cash & Equivalents has declined for 3 consecutive years, from $401M in FY2022 to $41M in FY2025.
Based on SEC 10-K filings.
$41M in FY2025 with a 3-year CAGR of -53.2%.
Declined from $158M to $41M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -53.2%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 9% in Health CareTop 91% of 207This company $41.2M Sector average $669.5M
▼
-93.9% below sector average
Key checks
Key Insights
- Zymeworks Inc.'s cash & equivalents has declined for 3 consecutive years.
- 3-year CAGR of -53.2%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 37.7% year-over-year.
- Ranks #189 out of 207 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -0.98 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $41.2M | -37.7% |
| FY2024 | $66.1M | -58.0% |
| FY2023 | $157.6M | -60.7% |
| FY2022 | $400.9M | +98.6% |
| FY2021 | $201.9M | - |
| FY2020 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026